Please enable JavaScript.
Coggle requires JavaScript to display documents.
SGLT-2 Inhibitors & GLP-1 Receptor Agonists in MASLD/MASH - Coggle…
SGLT-2 Inhibitors & GLP-1 Receptor Agonists in MASLD/MASH
Key actions of SGLT-2 Inhibitors in MASLD/MASH
✅ Key Actions:
Reduces hepatic fat accumulation by decreasing hepatic triglyceride content
Reduces inflammation by lowering pro-inflammatory cytokines (TNF-α, IL-6)
Decreases oxidative stress by improving mitochondrial function and reducing lipid peroxidation
Slows fibrosis progression by reducing hepatic stellate cell activation and modulating TGF-β signaling
Key trials of SGLT-2 Inhibitors in MASLD/MASH
✅ Key Trials & Evidence:
Meta-analyses & RCTs show:
↓ Hepatic steatosis (MRI-PDFF)
↓ Liver enzymes (ALT, AST)
↓ Fibrosis progression (elastography-based studies suggest improvements)
Cardiovascular & renal benefits (evidence from large diabetes trials)
Key actions of GLP-1 Receptor Agonists in MASLD/MASH
✅ Key Actions:
Promotes weight loss by suppressing appetite and enhancing satiety
Improves insulin sensitivity by reducing hepatic gluconeogenesis and increasing glucose uptake
Reduces hepatic fat accumulation by stimulating fat oxidation and decreasing de novo lipogenesis
Suppresses inflammation by downregulating NF-κB and reducing levels of TNF-α, IL-6
Slows fibrosis progression by reducing hepatic stellate cell activation and collagen deposition
Key trials of GLP-1 Receptor Agonists in MASLD/MASH
✅ Key Trials & Evidence:
Recent RCTs & Meta-analyses show:
↓ Liver fat accumulation (MRI-based and histological assessments)
↓ ALT, AST, CRP (biomarkers of liver injury and inflammation)
↓ Fibrosis markers
Particularly effective in MASLD patients with T2DM